ARL6IP6

Across TCGA pan-cancer cohorts, ARL6IP6 RNA differs between tumor and matched normal tissue in 15 of 18 cancer types tested, making tumor–normal expression one of ARL6IP6’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where ARL6IP6 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types ARL6IP6 is over-expressed in tumor, although a few such as KICH and PRAD show the opposite, repressed pattern.

HNSC, BLCA, and KIRC are the cancer types where ARL6IP6 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ARL6IP6 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	Male	III,IV	+1.268	<.001	12	view →
BLCA	All	III,IV	+1.193	<.001	11	view →
KIRC	Male	IV	+0.832	<.001	11	view →
STAD	Female	All	+1.128	<.001	9	view →
LIHC	All	III,IV	+0.908	<.001	9	view →
COAD	Male	All	+0.592	<.001	9	view →
KIRP	All	II,III,IV	+0.951	<.001	8	view →
LUSC	Female	All	+1.081	<.001	6	view →
CHOL	Male	All	+2.406	<.001	5	view →
KICH	Female	All	−1.384	<.001	5	view →
BRCA	All	II,III,IV	+0.267	.001	4	view →
READ	All	All	+0.736	<.001	3	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 15 lineages.

ARL6IP6–HNSC

Open the HNSC breakdown →